Back

Optimal thromboprophylaxis and anticoagulant strategies in patients with COVID-19 pneumonia. The PROTHROMCOVID Trial.

29 August 2022 (16:15 - 17:00)
Organised by:
Congress Presentation Part of: Covid-19 impact and management in patients with congenital heart disease and in patients with pulmonary hypertension Venous Thromboembolism ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Nuria Munoz-Rivas

University Hospital Infanta Leonor, Madrid (Spain)

5 More presentations in this session

Presentation thumbnail
Impact of coronavirus disease 2019 on adult patients with congenital heart disease
Doctor I. Cardoso (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Adults with congenital heart disease and COVID-19
Miss N. Langes (Munich, DE)
Abstract Slides
Presentation thumbnail
COVID-19 infection and its impact on case-fatality in patients with pulmonary embolism
Doctor L. Hobohm (Mainz, DE)
Abstract Slides
Presentation thumbnail
Impact of COVID-19 pandemics upon nationwide pulmonary hypertension cohort: 18-months analysis of BNP-PL national database.
Doctor A. Mamzer (Lodz, PL)
Abstract Slides
Presentation thumbnail
COVID-19 vaccination in adults with congenital heart disease: results of 1-year prospective study
Doctor A. Roma (Naples, IT)
Abstract Slides

Access the full session

Session thumbnail
Covid-19 impact and management in patients with congenital heart disease and in patients with pulmonary hypertension

The Event

Event poster

ESC Congress 2022

29 August 2022 16:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources